Clinical Trials List
2025-04-01 - 2035-12-31
Phase II
Recruiting3
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/07/01
Investigators and Locations
Co-Principal Investigator
- 陳慧雯 無
- Wei-Pang Chung 無
- 楊舜如 無
- 黃怡璇 無
- 魏慈慧 無
- Chun-Hui Lee Division of General Surgery
- 黃怡菁 無
- Zhu-Jun Loh 無
- Shang-Hung Chen Division of General Surgery
- Jui-Hung Tsai 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Kuan-Der Lee 無
- 劉佳樺 無
- HSIN-CHEN LIN 無
- 楊捷儒 無
- Chi-Long Chen 無
- ZHENG-WEI ZHOU 無
- Huey-En Tzeng 無
- I-Chen Tsai 無
- 王國鐘 無
- 林慈恩 無
- 楊陽生 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
17 participants
-
Global
372 participants
